BioSpace News Archive

Neurocrine reported net product sales of $45.8M for the three months ended September 30, 2017.

Reported preclinical data and clinical case studies showed that BLU-285 is a potent and highly selective inhibitor of KIT and PDGFR kinases, which are implicated in multiple diseases including GIST and SM.

Tocagen today announced it will report its third quarter 2017 financial results and business progress on Wednesday, November 8, 2017, after the close of the U.S. financial markets.

The completion of these transactions improves Windtree’s balance sheet and better positions the Company to raise the capital needed to fund continued development of AEROSURF for RDS and potentially its pipeline of surfactant products utilizing its proprietary KL4 surfactant and aerosol device technologies.

DURECT Corporation today announced financial results for the three months ended September 30, 2017 and provided a corporate update.

Synthetic Biologics today provided an operational update and reported financial results for the three months ended September 30, 2017.

The recent order of GlucoTrack, in the amount of US$460,000, was a re-order from an existing customer and represents a nearly two-fold increase from the original order.

The Company’s strategy of increasing its focus on new customers in the much larger “Early Majority” market segment resulted in new customers representing three-quarters of the all-tissue laser systems sales during the third quarter of 2017.

Foundation Medicine reported total revenue of $42.7 million in the third quarter of 2017, compared to $29.4 million in the third quarter of 2016.

Revenue for the three and nine months ended September 30, 2017 was $44.8 million and $85.4 million, compared to $20.8 million and $58.2 million for the three and nine months ended September 30, 2016, respectively.